These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 34592391

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR, Essa H, Austin P, Preston F, Kargbo I, Ibarburu GH, Ghuman R, Cuthbertson DJ, Lip GYH, Alam U.
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [Abstract] [Full Text] [Related]

  • 4. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.
    Wu T, Wong CKH, Tang EHM, Man KKC, Wong SKH, Au ICH, Tse ETY, Chan EWY, Grieve E, Wu O, Ng EKW, Wong ICK.
    Surg Obes Relat Dis; 2022 Jun; 18(6):762-771. PubMed ID: 35300912
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B, Grams ME, Chang A, Inker LA, Coresh J, Shin JI.
    Am J Cardiol; 2022 Feb 15; 165():124-130. PubMed ID: 34937658
    [Abstract] [Full Text] [Related]

  • 7. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
    Newman TV, Munshi KD, Neilson LM, Good CB, Swart ECS, Huang Y, Henderson R, Parekh N.
    J Manag Care Spec Pharm; 2021 Apr 15; 27(4):435-443. PubMed ID: 33769857
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F, Kazem N, Schweitzer R, Hammer A, Jakse F, Koller L, Hengstenberg C, Sulzgruber P, Niessner A.
    Cardiovasc Drugs Ther; 2021 Dec 15; 35(6):1161-1170. PubMed ID: 33666822
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND.
    JAMA Netw Open; 2021 Feb 01; 4(2):e2035792. PubMed ID: 33523188
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
    Lin J, Pearson SA, Greenfield JR, Park KH, Havard A, Brieger D, Day RO, Falster MO, de Oliveira Costa J.
    Eur J Clin Pharmacol; 2023 Sep 01; 79(9):1239-1248. PubMed ID: 37449993
    [Abstract] [Full Text] [Related]

  • 15. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B.
    Cardiovasc Diabetol; 2023 Apr 01; 22(1):79. PubMed ID: 37005640
    [Abstract] [Full Text] [Related]

  • 16. Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
    de Oliveira Costa J, Lin J, Milder TY, Greenfield JR, Day RO, Stocker SL, Neuen BL, Havard A, Pearson SA, Falster MO.
    Diabetes Obes Metab; 2024 Jul 01; 26(7):2787-2795. PubMed ID: 38618983
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH, Chang CH, Lin JW, Yang WS, Wu LC, Toh S.
    Diabetes Obes Metab; 2022 Aug 01; 24(8):1623-1637. PubMed ID: 35491533
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
    Edwards K, Li X, Lingvay I.
    J Clin Endocrinol Metab; 2023 Mar 10; 108(4):920-930. PubMed ID: 36268825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.